Insiders who reported open-market trades in the last 12 months at the companies Jon Faiz Kayyem files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Mark Lappe - $3.64M in INBX purchases and sales in the last 12 months
Douglas Forsyth - $287K in INBX purchases and sales in the last 12 months
Kimberly Manhard - $279K in INBX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Jon Faiz Kayyem is a corporate insider, tracked as Director of Inhibrx Biosciences, Inc. (INBX). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Jon Faiz Kayyem submitted recently?
4 primary Form 4 filings in the last 90 days, covering 1 company.
Has Jon Faiz Kayyem been buying or selling stock?
Recorded transactions: 7 open-market purchases ($3.09M) and 0 open-market sales across all tracked filings.
Jon Faiz Kayyem is Director of Inhibrx Biosciences, Inc. (INBX). 9 SEC Form 4 filings on record going back to 2024, most recently on 23 September 2026. Most recent open-market trade: bought $500K of INBX on 23 September 2026. Lifetime open-market purchases: $3.09M.
Recent transactions
11
The latest 11 SEC Form 4 transactions reported by Jon Faiz Kayyem.
InsiderAlpha's records for Jon Faiz Kayyem go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. The typical open-market purchase is $442K (7 buys totaling $3.09M). The largest single buy on record is $568K of INBX in 2026. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
